NCT07651891RecruitingPhase 4
Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
STUDY DESIGN A single-center prospective before-and-after study evaluating the effect of Alutard SQ Dog in 40 men and women with moderate-to-severe dog allergy. Participants will serve as their own controls. STUDY OUTLINE The study will begin in the fall of 2026 and will be conducted over a one-year period. At baseline, participants will be asked to record their allergic symptoms, and assessments of lung function and nasal airflow will be performed. Blood samples will also be collected. Following the baseline assessments, participants will undergo allergen provocation by entering a facility containing dogs. After a 30-minute exposure to dogs, participants will again be asked to record their allergic symptoms and will undergo the same assessments performed at baseline. Allergen immunotherapy (AIT) with Alutard SQ Dog will then be initiated according to the standard treatment regimen and continued for one year. At the end of the treatment period, the same provocation procedure and assessments will be repeated. Participants will enter a facility containing dogs, followed by symptom recording and evaluation of lung function, nasal airflow, and relevant laboratory parameters.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 11 Jun 2026
- Start date
- 1 Aug 2026
- Primary completion date
- 1 Oct 2027
- Lead sponsor
- Karolinska Institutet
- Diseases
- Asthma
- NCT number
- NCT07651891
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 40
- From 1 Aug 2026 to the primary completion date, 1 Oct 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with medications that may interfere with the immune response.
- Previous immunotherapy or chemotherapy.
Other illness
- Autoimmune or connective tissue disease.
- Cardiovascular disease.
- Hepatic disease.
- Renal disease.
- Malignancy.
- Upper airway disease (e.g., non-allergic sinusitis or nasal polyposis).
- Chronic obstructive or restrictive lung disease.
- Significant chronic disease.
- Major metabolic disease.
- Known or suspected hypersensitivity to the study product.
- Suspected or confirmed bacterial infection.
- Clinically relevant allergy to house dust mite.
- Any condition that, in the investigator's opinion, may make participation, follow-up, or study assessments inappropriate.
Other
- Pregnancy or breastfeeding.
- Alcohol or substance abuse.
- Mental or cognitive incapacity that may impair compliance with study procedures.
- Current dog ownership.
- Any subject considered unsuitable for enrolment according to the principles of the Declaration of Helsinki.
Who the study is looking for
- The subject has provided written informed consent to participate in the study.
- Age 18-50 years.
- Moderate-to-severe allergic symptoms upon exposure to dogs.
- Dog allergy confirmed by positive specific IgE.
- Considered suitable by the investigator for treatment with Alutard SQ Dog in accordance with the approved Summary of Product Characteristics (SmPC).
- Female subjects of childbearing potential must use adequate contraception.
- A negative pregnancy test must be obtained prior to enrolment.
Age in the registry: 18 years to 50 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Lund University Hospital Coordinator of this site? Confirm its status | Lund | Sweden | Recruiting |
| Trelleborg Hospital Coordinator of this site? Confirm its status | Trelleborg | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.